The BA.3.2 Omicron variant, a significantly mutated descendant of the virus, has now been detected in 29 US states and Puerto Rico, according to the latest data from the US Centers for Disease Control and Prevention. Its presence underscores the virus’s continued evolution but, health authorities stress, not a cause for immediate public alarm.
A Variant Marked by Sudden Change
First identified in a respiratory sample from a five-year-old in South Africa on 22 November 2024, BA.3.2 is what scientists term a “highly divergent” subvariant. Phylogenetic analysis suggests it may have emerged as far back as late 2023 before being caught by surveillance. It represents a descendant of the BA.3 Omicron lineage, which largely disappeared in early 2022, leading some researchers to informally dub BA.3.2 “Cicada” for its pattern of re-emergence.
The variant’s most striking feature is its heavily altered spike protein, which the virus uses to enter human cells. It carries more than 50 new mutations compared to its BA.3 parent and approximately 70 to 75 changes relative to more recent strains like JN.1. Researchers from the World Health Organization (WHO) believe this points to a potential ‘saltation event’—a sudden evolutionary leap, possibly occurring during a prolonged infection in a single individual.
Global Spread Without Clear Dominance
Since its detection, BA.3.2 has spread to at least 23 countries. It entered the United States via the Traveler-Based Genomic Surveillance programme, which identified it in a participant arriving from the Netherlands on 27 June 2025, with the first clinical cases in US patients reported last December. In parts of Europe, notably Denmark, Germany, and the Netherlands, it rose to account for around 30% of sequenced cases between November 2025 and January this year.
However, the CDC notes it still represents a low percentage of overall analysed US infections. Crucially, it has not shown a sustained growth advantage to rapidly overtake other co-circulating variants, a point underscored by the WHO’s classification of BA.3.2 as a “Variant Under Monitoring”—its lowest alert tier.
Immune Evasion and Protection Against Severe Disease
The constellation of spike mutations has a clear consequence: immune evasion. Early laboratory studies indicate that antibodies from vaccination or prior infection are less effective at neutralising BA.3.2 compared to other currently circulating strains. This means current vaccines may be less potent at preventing infection by this specific variant.
Yet, experts stress this does not equate to a loss of all protection. “The question that actually matters is whether BA.3.2 meaningfully erodes protection against severe disease,” says Dr Jake Scott, a Stanford infectious disease expert. He adds that all current evidence shows it does not. The reason lies in the body’s layered immune response. While antibodies targeting the spike can lose effectiveness, vaccines and prior infections also build a “deeper layer of immune memory” involving T-cells, which can recognise and fight the virus even after it mutates. Marc Veldhoen, an immunologist at the University of Lisbon, agrees current vaccines are working as intended against severe outcomes.
This scientific understanding informs public health posture. The WHO’s initial risk evaluation in December 2025 concluded BA.3.2 poses a “low additional public health risk.” Consequently, the WHO’s Technical Advisory Group on COVID-19 Vaccine Composition has flagged it for discussion regarding future vaccine updates, but for now, recommends continuing with existing vaccines, masking, and improved ventilation in high-risk settings.
Unpacking the Pediatric Pattern
One notable pattern has drawn researcher attention: BA.3.2 appears overrepresented in paediatric samples relative to adults in several countries. Data from the Global Initiative on Sharing All Influenza Data (Gisaid) database suggests this pattern is real, with independent analysis of New York City data indicating children may be up to five times more likely to be affected by BA.3.2 compared to other variants.
Experts, however, urge considerable caution in interpreting this. Dr Scott warns against leaping from “more commonly sequenced in children” to “preferentially infects children” in a clinically meaningful sense. He notes that sequencing data reflects who gets tested and whose samples get processed, not pure infection rates. Adults with mild infections are now far less likely to be tested or have samples sequenced, whereas symptomatic children are more likely to be tested in clinical settings where sequencing occurs.
An alternative biological explanation, noted by both Dr Scott and Professor Veldhoen, is that children have simply had less accumulated exposure to the myriad of Covid-19 variants over the years compared to adults, potentially leaving them with more susceptibility. “More importantly,” Dr Scott states, “there is no current signal that BA.3.2 is causing more severe disease in children.” The consensus is the pattern warrants monitoring but not catastrophising.
Symptoms, Severity, and Continued Vigilance
Reported symptoms for BA.3.2 align with those of other recent Omicron subvariants and typical respiratory infections: cough, fatigue, fever, headache, sore throat, and congestion. Less common symptoms include shortness of breath, nausea, and “brain fog.” Notably, loss of taste or smell is rarer with this variant. While there is no evidence it causes more severe disease, hospitalisations, or deaths at a population level, some clinical sources note it can cause severe dehydration from night sweats and diarrhoea, and may trigger dangerous inflammation in individuals with underlying conditions.
The variant’s ability to slip past some antibody defences means more people may experience infections, potentially raising concerns about a subsequent spike in Long Covid cases. For the moment, however, the message from experts is consistent. “The right response to BA.3.2 is serious attention, not alarm,” says Dr Scott. Professor Veldhoen adds that public health officials, doctors, and the general public do not need to change their behaviour, though vaccine researchers must continue tracking it. The Global Virus Network emphasises that current evidence does not indicate cause for heightened public concern, even as genomic surveillance continues to track the virus’s unpredictable evolution.